Eylea

Roche expands its PhIII program for Eylea rival as long-acting data back its blockbuster contender faricimab
Roche expands its PhIII program for Eylea rival as long-acting data back its blockbuster contender faricimab
Endpoints
Roche
Genentech
Regeneron
Novartis
Eylea
faricimab
wet-AMD
Flag link:
Regeneron and Roche Duke it Out in the Diabetic Retinopathy Market
Regeneron and Roche Duke it Out in the Diabetic Retinopathy Market
BioSpace
Regeneron
Eylea
diabetic retinopathy
Roche
Lucentis
Flag link:
FDA kicks Regeneron’s latest Eylea application to the curb, but they’re not sweating it
FDA kicks Regeneron’s latest Eylea application to the curb, but they’re not sweating it
Endpoints
Regeneron
FDA
Eylea
complete response letter
Flag link:
FDA to review Regeneron’s Eylea for diabetic retinopathy
FDA to review Regeneron’s Eylea for diabetic retinopathy
Drug Delivery Business News
Regeneron
FDA
Eylea
diabetic retinopathy
Flag link:
Just a few days after a stumble, FDA OKs 12-week dose for Eylea as Regeneron braces for Novartis attack
Just a few days after a stumble, FDA OKs 12-week dose for Eylea as Regeneron braces for Novartis attack
Endpoints
FDA
Eylea
Regeneron
Novartis
wet age-related macular degeneration
Flag link:
Racing Novartis on Eylea rival, the FDA trips up Regeneron at the finish line
Racing Novartis on Eylea rival, the FDA trips up Regeneron at the finish line
Endpoints
Regeneron
Eylea
Novartis
RTH258
wet age-related macular degeneration
FDA
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates And IPOs
The Week Ahead In Biotech: Conferences, PDUFA Dates And IPOs
Yahoo/Benzinga
biotech
IPOs
Pain Therapeutics
Remoxy
Vertex Pharmaceuticals
lumacaftor/ivacaftor
Alnylam
Patisiran
Regeneron
Eylea
Insmed
Paratek
Vaccinex
Flag link:
Regeneron plots DTC advertising and discount push to put Eylea back on track
Regeneron plots DTC advertising and discount push to put Eylea back on track
Fierce Pharma
Regeneron
Sanofi
Eylea
DTC advertising
Flag link:
Allergan’s eye contender cannot knock Eylea off its perch
Allergan’s eye contender cannot knock Eylea off its perch
EP Vantage
Regeneron
Eylea
wet age-related macular degeneration
Allergan
molecular
abicipar
Flag link:
Regeneron Focuses on Expanding Eylea’s Diabetic Retinopathy Label
Regeneron Focuses on Expanding Eylea’s Diabetic Retinopathy Label
Market Realist
Regeneron
FDA
Eylea
diabetic retinopathy
Flag link:
3 Reasons Regeneron Stock Could Start Climbing Again
3 Reasons Regeneron Stock Could Start Climbing Again
Yahoo/Motley Fool
Sanofi
Regeneron
Praluent
Dupixent
Eylea
Flag link:
Eyeing Eylea’s $5B sales, Novartis touts solid 12-week dosing data for its rival RTH258
Eyeing Eylea’s $5B sales, Novartis touts solid 12-week dosing data for its rival RTH258
Endpoints
Novartis
Regeneron
Eylea
RTH258
wet age-related macular degeneration
Flag link:
Novartis sues Regeneron over manufacturing methods
Novartis sues Regeneron over manufacturing methods
Biopharma Dive
Novartis
Regeneron
drug manufacturing
Zaltrap
Eylea
Flag link:
Regeneron’s Eylea Shows Promise in Late-Stage Diabetic Retinopathy Trial
Regeneron’s Eylea Shows Promise in Late-Stage Diabetic Retinopathy Trial
Xtalks
Regeneron
Eylea
diabetic retinopathy
Flag link:
With Novartis and Roche gunning to carve up Eylea franchise, Regeneron has another PhIII success story to tell
With Novartis and Roche gunning to carve up Eylea franchise, Regeneron has another PhIII success story to tell
Endpoints
Novartis
Roche
Eylea
Regeneron
Flag link:
Here's What Weighed on Regeneron Pharmaceuticals Inc. in February
Here's What Weighed on Regeneron Pharmaceuticals Inc. in February
Motley Fool
Regeneron
Eylea
Flag link:
Regeneron vision drug Eylea sees upward tick in unexplained side-effect cases
Regeneron vision drug Eylea sees upward tick in unexplained side-effect cases
Fierce Pharma
Regeneron
Eylea
side effects
Flag link:
Roche posts positive PhII results for bispecific antibody eye drug, joining Novartis in rivalry with Eylea
Roche posts positive PhII results for bispecific antibody eye drug, joining Novartis in rivalry with Eylea
Endpoints
Roche
bispecific antibodies
RG7716
Novartis
Eylea
Flag link:
Mylan, Momenta take aim at Regeneron’s Eylea with biosimilar
Mylan, Momenta take aim at Regeneron’s Eylea with biosimilar
Drug Delivery Business News
Mylan Labs
Momenta Pharmaceuticals
Regeneron
Eylea
biosimilars
diabetic macular edema
wet age-related macular degeneration
M710
Flag link:
With Novartis closing in, Regeneron scraps Eylea combo drug in a major setback
With Novartis closing in, Regeneron scraps Eylea combo drug in a major setback
Endpoints
Novartis
Regeneron
Eylea
RTH258
nesvacumab
Bayer
Flag link:

Pages